Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Nat Methods ; 6(8): 593-5, 2009 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-19620973

RESUMO

We synthesized reversible terminators with tethered inhibitors for next-generation sequencing. These were efficiently incorporated with high fidelity while preventing incorporation of additional nucleotides, and we used them to sequence canine bacterial artificial chromosomes in a single-molecule system that provided even coverage for over 99% of the region sequenced. This single-molecule approach generated high-quality sequence data without the need for target amplification and thus avoided concomitant biases.


Assuntos
Cromossomos Artificiais Bacterianos/química , DNA/química , Nucleotídeos/química , Análise de Sequência de DNA/métodos , Animais , Cromatografia Líquida de Alta Pressão , Cromossomos Artificiais Bacterianos/genética , Simulação por Computador , Cães , Nucleotídeos/genética , Sensibilidade e Especificidade , Especificidade por Substrato
2.
Assay Drug Dev Technol ; 5(3): 381-90, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17638538

RESUMO

One of the major hurdles in the post-genomic era is to understand the function of genes and the interplay of many different cellular proteins. This is especially important for drug development. Capture compound mass spectrometry (CCMS) addresses this challenge by selectively reducing the complexity of the proteome. Capture compounds are trifunctional molecules: a selectivity function reversibly interacts via affinity with proteins; a reactivity function irreversibly forms a covalent bond outside the affinity binding site; and a sorting/pullout function allows the captured protein(s) to be isolated from cellular lysate for mass spectrometric analysis and characterization by database queries. In the present study, we demonstrate the use of a CCMS capture compound with a sulfonamide drug analog as its selectivity function, isolating an expected target protein from cell lysates containing a large excess of other "non-target" proteins. A future application of CCMS is to define or confirm drug target proteins and their mechanisms of drug action, or to discover off-target proteins that cause side effects, enabling subsequent drug structure optimization.


Assuntos
Desenho de Fármacos , Proteínas/análise , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz/métodos , Ligação Proteica , Sulfonamidas/metabolismo , Sulfonamidas/farmacologia
4.
Nucleosides Nucleotides ; 15(1-3): 693-717, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-27043138

RESUMO

The binding affinities at rat A1, A2a, and A3 adenosine receptors of a wide range of heterocyclic derivatives have been determined. Mono-, bi-, tricyclic and macrocyclic compounds were screened in binding assays, using either [3H]PIA or [3H]CGS 21680 in rat brain membranes or [125I]AB-MECA in CHO cells stably transfected with rat A3 receptors. Several new classes of adenosine antagonists (e.g. 5-oxoimidazopyrimidines and a pyrazoloquinazoline) were identified. Various sulfonylpiperazines, 11-hydroxytetrahydrocarbazolenine, 4H-pyrido[1,2-a]pyrimidinone, folic acid, and cytochalasin H and J bound to A3 receptors selectively. Moreover, cytochalasin A, which bound to A1 adenosine receptors with Ki value of 1.9 µM, inhibited adenylyl cyclase in rat adipocytes, but not via reversible A1 receptor binding.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA